The neuroprotective effects of progesterone on traumatic brain injury: current status and future prospects

被引:0
作者
Jing Wei
Guo-min Xiao
机构
[1] Medical Center,
[2] The Affiliated Hospital of Hangzhou Normal University,undefined
[3] Neurosurgery,undefined
[4] The Affiliated Hospital of Hangzhou Normal University,undefined
来源
Acta Pharmacologica Sinica | 2013年 / 34卷
关键词
progesterone; traumatic brain injury; neuroprotection; hormone;
D O I
暂无
中图分类号
学科分类号
摘要
Traumatic brain injury is the leading cause of morbidity and mortality in young adults. The secondary injury in traumatic brain injury consists of a complex cascade of processes that simultaneously react to the primary injury to the brain. This cascade has been the target of numerous therapeutic agents investigated over the last 30 years, but no neuroprotective treatment option is currently available that improve neurological outcome after traumatic brain injury. Progesterone has long been considered merely a female reproductive hormone. Numerous studies, however, show that progesterone has substantial pleiotropic properties as a neuroprotective agent in both animal models and humans. Here, we review the increasing evidence that progesterone can act as a neuroprotective agent to treat traumatic brain injury and the mechanisms underlying these effects. Additionally, we discuss the current progress of clinical studies on the application of progesterone in the treatment of traumatic brain injuries.
引用
收藏
页码:1485 / 1490
页数:5
相关论文
共 209 条
  • [1] Bramlett HM(2007)Progressive damage after brain and spinal cord injury: pathomechanisms and treatment strategies Prog Brain Res 161 125-41
  • [2] Dietrich WD(2013)A clinical/translational perspective: can a developmental hormone play a role in the treatment of traumatic brain injury? Horm Behav 63 291-300
  • [3] Stein DG(2010)Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies Trends Pharmacol Sci 31 596-604
  • [4] Loane DJ(2004)Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial Lancet 364 1321-8
  • [5] Faden AI(2005)Glucocorticoid therapy in neurologic critical care Crit Care Med 33 1214-24
  • [6] Roberts I(2007)Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial Lancet Neurol 6 29-38
  • [7] Yates D(2012)Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT) JAMA 308 1993-2000
  • [8] Sandercock P(2000)Doseresponse curve and optimal dosing regimen of cyclosporine A after traumatic brain injury in rats Neuroscience 101 289-95
  • [9] Farrell B(1991)Incidence and survival rates during a two-year period of intracerebral and subarachnoid haemorrhages, cortical infarcts, lacunes and transient ischaemic attacks the stroke registry of dijon: 1985–1989 Int J Epidemiol 20 892-9
  • [10] Wasserberg J(1998)Stroke incidence among white, black, and hispanic residents of an urban community: The northern manhattan stroke study Am J Epidemiol 147 259-68